JP2017514496A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514496A5 JP2017514496A5 JP2016566228A JP2016566228A JP2017514496A5 JP 2017514496 A5 JP2017514496 A5 JP 2017514496A5 JP 2016566228 A JP2016566228 A JP 2016566228A JP 2016566228 A JP2016566228 A JP 2016566228A JP 2017514496 A5 JP2017514496 A5 JP 2017514496A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- rodent
- mouse
- human
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461988581P | 2014-05-05 | 2014-05-05 | |
| US61/988,581 | 2014-05-05 | ||
| US201462067836P | 2014-10-23 | 2014-10-23 | |
| US62/067,836 | 2014-10-23 | ||
| PCT/US2015/029111 WO2015171523A1 (en) | 2014-05-05 | 2015-05-04 | Humanized c5 and c3 animals |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514496A JP2017514496A (ja) | 2017-06-08 |
| JP2017514496A5 true JP2017514496A5 (2) | 2018-06-28 |
| JP6598798B2 JP6598798B2 (ja) | 2019-10-30 |
Family
ID=53177902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016566228A Active JP6598798B2 (ja) | 2014-05-05 | 2015-05-04 | ヒト化ｃ５およびｃ３動物 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US9795121B2 (2) |
| EP (3) | EP3636073B1 (2) |
| JP (1) | JP6598798B2 (2) |
| KR (1) | KR102461511B1 (2) |
| CN (1) | CN106659146B (2) |
| AU (1) | AU2015256299C1 (2) |
| BR (1) | BR112016025751A2 (2) |
| CA (2) | CA3225091A1 (2) |
| ES (2) | ES2968749T3 (2) |
| IL (1) | IL248481B (2) |
| MA (1) | MA51519A (2) |
| MX (2) | MX2016014504A (2) |
| RU (2) | RU2713327C2 (2) |
| SG (2) | SG11201608696RA (2) |
| WO (1) | WO2015171523A1 (2) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| EP3636073B1 (en) | 2014-05-05 | 2023-11-15 | Regeneron Pharmaceuticals, Inc. | Humanized c5 and c3 animals |
| NO2785538T3 (2) | 2014-05-07 | 2018-08-04 | ||
| TWI870789B (zh) | 2015-08-04 | 2025-01-21 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| EP3407915A4 (en) * | 2016-01-25 | 2019-11-20 | President and Fellows of Harvard College | METHOD AND COMPOSITIONS FOR DETECTING AND TREATING SCHIZOPHRENIA |
| CN116769024A (zh) | 2016-06-14 | 2023-09-19 | 瑞泽恩制药公司 | 抗c5抗体及其用途 |
| EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| SG10202111663PA (en) * | 2017-02-27 | 2021-12-30 | Regeneron Pharma | Humanized model of kidney and liver disorders |
| BR112020000127A2 (pt) | 2017-07-06 | 2020-07-07 | Regeneron Pharmaceuticals, Inc. | método para selecionar um hidrolisado de soja, e, glicoproteína |
| CN107736281A (zh) * | 2017-09-29 | 2018-02-27 | 中国水产科学研究院珠江水产研究所 | 一种利用益生菌发酵酱油渣防治池塘养殖鳜鱼寄生虫的方法 |
| US20190098879A1 (en) * | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | Non-Human Animals Comprising A Humanized TTR Locus And Methods Of Use |
| RU2020112751A (ru) * | 2017-09-29 | 2021-10-29 | Регенерон Фармасьютикалз, Инк. | Отличные от человека животные, у которых экспрессируется гуманизированный комплекс c1q |
| CA3274059A1 (en) | 2017-12-13 | 2026-03-02 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
| MX2020006639A (es) | 2017-12-22 | 2020-09-14 | Regeneron Pharma | Sistema y metodo para caracterizar las impurezas de un producto farmaceutico. |
| BR112020013336A2 (pt) | 2018-01-31 | 2020-12-01 | Regeneron Pharmaceuticals, Inc. | produto farmacêutico proteico, métodos para caracterizar as impurezas do produto farmacêutico proteico de alto peso molecular intermediário, para produção de um anticorpo, e para caracterizar as impurezas de fármaco com variação de carga, anticorpo, e, sistema para caracterizar impurezas de fármaco de alto peso molecular intermediário. |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| WO2019168774A1 (en) | 2018-02-28 | 2019-09-06 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| HUE065344T2 (hu) | 2018-03-19 | 2024-05-28 | Regeneron Pharma | Mikrochip kapilláris elektroforézis assay-k és reagensek |
| JP7477457B2 (ja) | 2018-04-03 | 2024-05-01 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | Ｃ３結合薬及びその使用方法 |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| HRP20240999T1 (hr) | 2018-07-16 | 2024-10-25 | Regeneron Pharmaceuticals, Inc. | Glodavački modeli bolesti ditra i njihova upotreba |
| CN119264211A (zh) | 2018-08-27 | 2025-01-07 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| JP7511542B2 (ja) | 2018-08-30 | 2024-07-05 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | タンパク質複合体を特徴づけるための方法 |
| JP7653909B2 (ja) | 2018-09-06 | 2025-03-31 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ヒト化抗ｃ５抗体とその利用 |
| WO2020150491A1 (en) | 2019-01-16 | 2020-07-23 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing disulfide bonds |
| KR102661779B1 (ko) | 2019-04-04 | 2024-04-30 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 응고 인자 12 좌위를 포함하는 비-인간 동물 |
| EP3958901A4 (en) * | 2019-04-24 | 2023-07-19 | The Trustees of the University of Pennsylvania | BI-FUNCTIONAL HUMANIZED ANTI-C5 ANTIBODIES AND H-FACTOR FUSION PROTEINS AND THEIR USES |
| WO2020231992A1 (en) | 2019-05-13 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Improved competitive ligand binding assays |
| US11891618B2 (en) | 2019-06-04 | 2024-02-06 | Regeneron Pharmaceuticals, Inc. | Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use |
| MX2021015122A (es) | 2019-06-07 | 2022-04-06 | Regeneron Pharma | Animales no humanos que comprenden un locus de albumina humanizado. |
| WO2021061790A1 (en) | 2019-09-24 | 2021-04-01 | Regeneron Pharmaceuticals, Inc. | Systems and methods for chromatography use and regeneration |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| CA3158119A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| CN115398236B (zh) | 2020-01-21 | 2024-06-11 | 瑞泽恩制药公司 | 用于糖基化的蛋白质的电泳的去糖基化方法 |
| WO2022047108A1 (en) | 2020-08-31 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
| KR20230078677A (ko) | 2020-10-01 | 2023-06-02 | 리제너론 파마슈티칼스 인코포레이티드 | 인간 cr1을 발현하는 설치류 동물 |
| WO2022115588A1 (en) | 2020-11-25 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| KR20230121854A (ko) | 2020-12-17 | 2023-08-21 | 리제너론 파아마슈티컬스, 인크. | 단백질-캡슐화 마이크로겔의 제작 |
| MX2023008527A (es) | 2021-01-20 | 2023-07-28 | Regeneron Pharma | Metodos para mejorar el valor proteico en cultivo celular. |
| JP2024512299A (ja) | 2021-03-03 | 2024-03-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | タンパク質の粘度を定量及び変更するためのシステム及び方法 |
| AU2022243005A1 (en) | 2021-03-26 | 2023-10-05 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing mixing protocols |
| BR112023024984A2 (pt) | 2021-06-01 | 2024-02-20 | Regeneron Pharma | Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit |
| US20230077710A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS |
| CA3232463A1 (en) | 2021-09-20 | 2023-03-23 | Philip Mellors | Methods of controlling antibody heterogeneity |
| CA3230984A1 (en) | 2021-10-07 | 2023-04-13 | Ross BROWNE | Systems and methods of ph modeling and control |
| WO2023059803A1 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Ph meter calibration and correction |
| TW202330104A (zh) | 2021-10-26 | 2023-08-01 | 美商再生元醫藥公司 | 用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法 |
| US20240415980A1 (en) | 2021-10-28 | 2024-12-19 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-related methods and compositions for knocking out c5 |
| KR20240164561A (ko) | 2022-03-18 | 2024-11-19 | 리제너론 파아마슈티컬스, 인크. | 폴리펩타이드 변종을 분석하기 위한 방법 및 시스템 |
| TW202435942A (zh) | 2022-12-16 | 2024-09-16 | 美商里珍納龍藥品有限公司 | 評估層析管柱完整性的方法及系統 |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| EP4655595A1 (en) | 2023-01-25 | 2025-12-03 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| EP4669963A2 (en) | 2023-02-22 | 2025-12-31 | Regeneron Pharmaceuticals, Inc. | SYSTEM FITNESS PARAMETERS AND COLUMN AGING |
| US20240366471A1 (en) | 2023-05-01 | 2024-11-07 | Regeneron Pharmaceuticals, Inc. | Multidose antibody drug products using phenol or benzyl alcohol |
| WO2025054406A1 (en) | 2023-09-08 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| US20250095773A1 (en) | 2023-09-18 | 2025-03-20 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| US20250109905A1 (en) | 2023-09-29 | 2025-04-03 | Regeneron Pharmaceuticals, Inc. | Lyophilization using controlled nucleation |
| US20250129117A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| US20250145662A1 (en) | 2023-11-02 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| WO2025122669A1 (en) | 2023-12-05 | 2025-06-12 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized complement factor b gene |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| TW202602489A (zh) | 2024-03-15 | 2026-01-16 | 美商再生元醫藥公司 | 作為經穩定的蛋白質調配物之賦形劑的聚山梨醇酯及聚氧乙烯山梨糖醇酐 |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
| WO2026025028A1 (en) | 2024-07-26 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Methods of making ultra-high concentrated protein formulations using lyophilization |
| WO2026060350A1 (en) | 2024-09-13 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods |
| WO2026076201A2 (en) | 2024-10-03 | 2026-04-09 | Regeneron Pharmaceuticals, Inc. | Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools |
| WO2026080597A1 (en) | 2024-10-08 | 2026-04-16 | Regeneron Pharmaceuticals, Inc. | Sustained delivery of biologics and non-aqueous manufacture of same |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1984003506A1 (en) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Antigenically active amino acid sequences |
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| DE229046T1 (de) | 1985-03-30 | 1987-12-17 | Marc Genf/Geneve Ballivet | Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren. |
| NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5266684A (en) | 1988-05-02 | 1993-11-30 | The Reagents Of The University Of California | Peptide mixtures |
| US5571689A (en) | 1988-06-16 | 1996-11-05 | Washington University | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid |
| US5663143A (en) | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US5770434A (en) | 1990-09-28 | 1998-06-23 | Ixsys Incorporated | Soluble peptides having constrained, secondary conformation in solution and method of making same |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| AU668347B2 (en) | 1990-11-21 | 1996-05-02 | Torrey Pines Institute For Molecular Studies | Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5644048A (en) | 1992-01-10 | 1997-07-01 | Isis Pharmaceuticals, Inc. | Process for preparing phosphorothioate oligonucleotides |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US6166288A (en) * | 1995-09-27 | 2000-12-26 | Nextran Inc. | Method of producing transgenic animals for xenotransplantation expressing both an enzyme masking or reducing the level of the gal epitope and a complement inhibitor |
| GB9521943D0 (en) | 1995-10-26 | 1996-01-03 | Univ Hertfordshire | Coded particles for process sequence tracking in combinatorial compound library preparation |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
| US6280946B2 (en) | 1998-08-07 | 2001-08-28 | Boston Probes, Inc. | PNA probes, probe sets, methods and kits pertaining to the universal detection of bacteria and eucarya |
| CA2355215A1 (en) | 1998-12-28 | 2000-07-06 | Jim Wells | Identifying small organic molecule ligands for binding |
| WO2005060739A1 (en) | 2003-12-24 | 2005-07-07 | G2 Inflammation Pty Ltd | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar |
| BRPI0506629A (pt) | 2004-02-10 | 2007-05-02 | Univ Colorado | inibição do fator b, a via alternativa do sistema complemento e métodos relacionados |
| ES2463476T3 (es) | 2004-10-19 | 2014-05-28 | Regeneron Pharmaceuticals, Inc. | Método para generar un ratón homocigótico para una modificación genética |
| EP2384811A1 (en) | 2006-01-11 | 2011-11-09 | Novo Nordisk A/S | A spherical encoded bead with an ultrasonic identification chip |
| RU2010138612A (ru) * | 2008-02-20 | 2012-03-27 | Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| EP4502152A3 (en) | 2009-10-06 | 2025-04-30 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
| SG10202008003VA (en) | 2011-02-15 | 2020-10-29 | Regeneron Pharma | Humanized m-csf mice |
| SMT201900478T1 (it) | 2011-10-28 | 2019-09-09 | Regeneron Pharma | Topi con complesso maggiore di istocompatibilita' geneticamente modificati |
| CN108866101A (zh) | 2011-10-28 | 2018-11-23 | 瑞泽恩制药公司 | 人源化il-6和il-6受体 |
| US8962913B2 (en) * | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
| FI2892330T3 (fi) | 2012-09-07 | 2023-03-25 | Univ Yale | Geneettisesti muokattuja hiiriä ja menetelmiä niiden käyttämiseksi |
| MX377561B (es) | 2012-11-05 | 2025-03-10 | Regeneron Pharma | Animales no humanos genéticamente modificados y métodos de uso de los mismos. |
| EP3699190B9 (en) | 2013-02-22 | 2023-10-04 | Regeneron Pharmaceuticals, Inc. | Murine cell expressing humanized major histocompatibility complex |
| ES2613379T3 (es) | 2013-10-15 | 2017-05-24 | Regeneron Pharmaceuticals, Inc. | Animales con IL-15 humanizada |
| RU2671101C1 (ru) | 2013-11-19 | 2018-10-29 | Регенерон Фармасьютикалс, Инк. | Отличные от человека животные, содержащие гуманизированный ген индуцирующего пролиферацию лиганда |
| EP3636073B1 (en) | 2014-05-05 | 2023-11-15 | Regeneron Pharmaceuticals, Inc. | Humanized c5 and c3 animals |
-
2015
- 2015-05-04 EP EP19211905.5A patent/EP3636073B1/en active Active
- 2015-05-04 SG SG11201608696RA patent/SG11201608696RA/en unknown
- 2015-05-04 CA CA3225091A patent/CA3225091A1/en active Pending
- 2015-05-04 EP EP23202404.2A patent/EP4317445A3/en not_active Withdrawn
- 2015-05-04 ES ES19211905T patent/ES2968749T3/es active Active
- 2015-05-04 SG SG10202003996YA patent/SG10202003996YA/en unknown
- 2015-05-04 BR BR112016025751A patent/BR112016025751A2/pt not_active Application Discontinuation
- 2015-05-04 WO PCT/US2015/029111 patent/WO2015171523A1/en not_active Ceased
- 2015-05-04 MA MA051519A patent/MA51519A/fr unknown
- 2015-05-04 JP JP2016566228A patent/JP6598798B2/ja active Active
- 2015-05-04 KR KR1020167032659A patent/KR102461511B1/ko active Active
- 2015-05-04 MX MX2016014504A patent/MX2016014504A/es active IP Right Grant
- 2015-05-04 ES ES15722639T patent/ES2779070T3/es active Active
- 2015-05-04 US US14/703,818 patent/US9795121B2/en not_active Expired - Fee Related
- 2015-05-04 MX MX2019013850A patent/MX386644B/es unknown
- 2015-05-04 EP EP15722639.0A patent/EP3142483B1/en active Active
- 2015-05-04 AU AU2015256299A patent/AU2015256299C1/en not_active Ceased
- 2015-05-04 CN CN201580034127.8A patent/CN106659146B/zh not_active Expired - Fee Related
- 2015-05-04 CA CA2946412A patent/CA2946412C/en active Active
- 2015-05-04 RU RU2016146390A patent/RU2713327C2/ru active
- 2015-05-04 RU RU2020103811A patent/RU2020103811A/ru unknown
-
2016
- 2016-10-25 IL IL248481A patent/IL248481B/en active IP Right Grant
-
2017
- 2017-07-26 US US15/660,833 patent/US10492477B2/en active Active
-
2018
- 2018-07-02 US US16/025,377 patent/US10524458B2/en active Active
-
2019
- 2019-10-21 US US16/658,541 patent/US11178860B2/en not_active Expired - Fee Related
-
2021
- 2021-10-20 US US17/505,834 patent/US20220132818A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514496A5 (2) | ||
| RU2020103811A (ru) | Гуманизированные животные по с5 и с3 | |
| Bendixen et al. | CRISPR-Cas-mediated transcriptional modulation: The therapeutic promises of CRISPRa and CRISPRi | |
| EP4414988A3 (en) | Methods, systems, and software for identifying bio-molecules using models of multiplicative form | |
| PH12016500342A1 (en) | Non-human animals having a humanized signal-regulatory protein gene | |
| PH12017501887A1 (en) | Pesticidal genes and methods of use | |
| JP2014039567A5 (2) | ||
| AR102888A1 (es) | Animales no humanos que tienen un gen humanizado de agrupamiento de diferenciación 47 | |
| BR112016006261A2 (pt) | camundongo, célula ou tecido de camundongo isolado, e, métodos para produzir um camundongo, para enxertar células humanas em um camundongo e para avaliar a eficácia terapêutica de uma droga que alveja células humanas | |
| HRP20202034T1 (hr) | Neljudske životinje s genom za humanizirani diferencijacijski biljeg cd274 | |
| MY185881A (en) | Non-human animals with modified immunoglobulin heavy chain sequences | |
| SG10201906673WA (en) | Artificial nucleic acid molecules | |
| HRP20200613T1 (hr) | Neljudske životinje koje imaju humanizirani gen 1 za programiranu staničnu smrt | |
| EP4345163A3 (en) | Genetic engineering of non-human animals for the production of chimeric antibodies | |
| JP2017501211A5 (2) | ||
| MX387036B (es) | Animales con dipeptidil peptidasa iv (dpp4) humanizada | |
| PH12018501338A1 (en) | Pesticidal genes and methods of use | |
| AR072495A1 (es) | Secuencia reguladora de las plantas proveniente de un gen de maiz | |
| JP2016519575A5 (2) | ||
| PH12017501148A1 (en) | Pesticidal genes and methods of use | |
| EA201690634A1 (ru) | Новая гетеро-трансгликозилаза и ее применение | |
| PH12021550691A1 (en) | Pesticidal genes and methods of use | |
| WO2014146181A3 (pt) | Promotor específico de folhas, gene quimérico, vetor de recombinante, planta ou parte de planta transformada e métodos contendo promotor específico de folhas para modificar a expressão de genes de interesse em plantas | |
| NZ726602B2 (en) | Humanized c5 and c3 animals | |
| NZ763860B2 (en) | Humanized c5 and c3 animals |